GWM
VNDA icon

Geneos Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Geneos Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$25K – 2467
2018
Q4 		$25K Buy
1,000
+500
+100% +$11.8K ﹤0.01% 1411
2018
Q3 		$11K Buy
+500
New +$10.2K ﹤0.01% 1818

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geneos Wealth Management's VNDA Position: Q1 2019 in Review

Geneos Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 1,000 shares — an estimated $25K sold.

Geneos Wealth Management first reported a position in VNDA in Q3 2018 and held it in 2 quarters. The position peaked at $25K in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • Geneos Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Geneos Wealth Management sold 1,000 Vanda Pharmaceuticals shares in Q1 2019, an estimated $25K.
  • Geneos Wealth Management first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Geneos Wealth Management's Vanda Pharmaceuticals position peaked at $25K in Q4 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Geneos Wealth Management's 13F filing for Q1 2019, filed 7 Sep 2021.